Ashish Upadhyay

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2651456/publications.pdf

Version: 2024-02-01

26	3,380	567281 15	552781 26
papers	citations	h-index	g-index

26	26	26	5624
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Incidence and Prevalence of Hyponatremia. American Journal of Medicine, 2006, 119, S30-S35.	1.5	603
2	Multiple loci associated with indices of renal function and chronic kidney disease. Nature Genetics, 2009, 41, 712-717.	21.4	553
3	Impact of Hospital-Associated Hyponatremia on Selected Outcomes. Archives of Internal Medicine, 2010, 170, 294.	3.8	429
4	Risk of Thromboembolism With Short-term Interruption of Warfarin Therapy. Archives of Internal Medicine, 2008, 168, 63.	3.8	307
5	Systematic Review: Blood Pressure Target in Chronic Kidney Disease and Proteinuria as an Effect Modifier. Annals of Internal Medicine, 2011, 154, 541.	3.9	292
6	Multiple Genetic Loci Influence Serum Urate Levels and Their Relationship With Gout and Cardiovascular Disease Risk Factors. Circulation: Cardiovascular Genetics, 2010, 3, 523-530.	5.1	285
7	Epidemiology of Hyponatremia. Seminars in Nephrology, 2009, 29, 227-238.	1.6	206
8	Lipid-Lowering Therapy in Persons With Chronic Kidney Disease. Annals of Internal Medicine, 2012, 157, 251.	3.9	146
9	Arterial Stiffness in Mild-to-Moderate CKD. Journal of the American Society of Nephrology: JASN, 2009, 20, 2044-2053.	6.1	127
10	Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrology Dialysis Transplantation, 2011, 26, 920-926.	0.7	117
11	Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney International, 2018, 93, 1397-1408.	5.2	83
12	Predictors of Incident Albuminuria in the Framingham Offspring Cohort. American Journal of Kidney Diseases, 2010, 56, 852-860.	1.9	48
13	Single-Use versus Reusable Dialyzers. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1079-1086.	4.5	44
14	Assessment of Proteinuria. Advances in Chronic Kidney Disease, 2011, 18, 243-248.	1.4	44
15	Renal Artery Calcium, Cardiovascular Risk Factors, and Indexes of Renal Function. American Journal of Cardiology, 2014, 113, 156-161.	1.6	23
16	We Use Impure Water to Make Dialysate for Hemodialysis. Seminars in Dialysis, 2016, 29, 297-299.	1.3	17
17	Association of Mildly Reduced Kidney Function With Cardiovascular Disease: The Framingham Heart Study. Journal of the American Heart Association, 2021, 10, e020301.	3.7	13
18	Reuse and Biocompatibility of Hemodialysis Membranes: Clinically Relevant?. Seminars in Dialysis, 2017, 30, 121-124.	1.3	9

#	Article	IF	Citations
19	Lipid-Lowering Therapy in Individuals With CKD: Lessons Learned From SHARP. American Journal of Kidney Diseases, 2012, 59, 170-173.	1.9	7
20	Is the lower blood pressure target for patients with chronic kidney disease supported by evidence?. Current Opinion in Cardiology, 2012, 27, 370-373.	1.8	5
21	Statins in chronic kidney disease: what do meta-analyses tell us?. Clinical and Experimental Nephrology, 2014, 18, 278-281.	1.6	5
22	CREDENCE: Significant Victory for Diabetic Kidney Disease. Trends in Endocrinology and Metabolism, 2020, 31, 391-393.	7.1	5
23	Ultrapure versus standard dialysate: A costâ€benefit analysis. Seminars in Dialysis, 2017, 30, 398-402.	1.3	4
24	End-stage kidney disease and COVID-19 in an urban safety-net hospital in Boston, Massachusetts. PLoS ONE, 2021, 16, e0252679.	2.5	4
25	Dialyzer reuse: is it safe and worth it?. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2019, 41, 312-314.	0.9	3
26	Risk of thromboembolism with short-term interruption of warfarin. Journal of Thrombosis and Thrombolysis, 2008, 25, 116-116.	2.1	1